Alternative Donor Transplant of Benign Primary Hematologic Disorders

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2015 Feb 10

PMID 25665040

Citations 6

Authors

J Tolar

P Sodani

H Symons

Affiliations

Soon will be listed here.

Abstract

Hematopoietic SCT is currently the only curative therapy for a range of benign inherited and acquired primary hematologic disorders in children, including BM failure syndromes and hemoglobinopathies. The preferred HLA-matched sibling donor is available for only about 25% of such children. However, there has been substantial progress over the last four decades in the use of alternative donors for those without a matched sibling-including HLA-matched unrelated donors, HLA-haploidentical related donors and unrelated-donor umbilical cord blood-so that it is now possible to find a donor for almost every child requiring an allograft. Below, we summarize the relative merits and limitations of the different alternative donors for benign hematologic conditions, first generally, and then in relation to specific disorders, and suggest recommendations for selecting such an alternative donor.

Citing Articles

A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.

Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, Ayuk F Transplant Cell Ther. 2024; 30(6):603.e1-603.e11.

PMID: 38548227 PMC: 11139591. DOI: 10.1016/j.jtct.2024.03.022.

T-cell replete Haplo-identical HSCT with Post transplant Cyclophosphamide for Hemoglobinopathies: A retrospective analysis from a single center.

Choudhary D, Doval D, Sharma S, Khandelwal V, Setia R, Handoo A Blood Cell Ther. 2023; 4(2):29-34.

PMID: 36712899 PMC: 9847306. DOI: 10.31547/bct-2020-014.

KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection.

Dhuyser A, Aarnink A, Peres M, Jayaraman J, Nemat-Gorgani N, Rubio M Front Immunol. 2022; 13:821533.

PMID: 35242134 PMC: 8886110. DOI: 10.3389/fimmu.2022.821533.

Review of Haploidentical Hematopoietic Cell Transplantation.

Khan M, Bashir Q, Chaudhry Q, Ahmed P, Satti T, Mahmood S J Glob Oncol. 2018; 4:1-13.

PMID: 30521413 PMC: 7010419. DOI: 10.1200/JGO.18.00130.

Regenerative Solutions for Inherited Diseases.

Tolar J Clin Pharmacol Ther. 2018; 103(5):763-766.

PMID: 29380353 PMC: 9309030. DOI: 10.1002/cpt.990.

References

Iannone R, Casella J, Fuchs E, Chen A, Jones R, Woolfrey A . Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003; 9(8):519-28. DOI: 10.1016/s1083-8791(03)00192-7. View

Lu D, Dong L, Wu T, Huang X, Zhang M, Han W . Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2005; 107(8):3065-73. DOI: 10.1182/blood-2005-05-2146. View

Islam A, Rafiq S, Kirwan M, Walne A, Cavenagh J, Vulliamy T . Haematological recovery in dyskeratosis congenita patients treated with danazol. Br J Haematol. 2013; 162(6):854-6. DOI: 10.1111/bjh.12432. View

Sauter C, Rausen A, Barker J . Successful unrelated donor cord blood transplantation for adult sickle cell disease and Hodgkin lymphoma. Bone Marrow Transplant. 2009; 45(7):1252. DOI: 10.1038/bmt.2009.317. View

Luznik L, Bolanos-Meade J, Zahurak M, Chen A, Smith B, Brodsky R . High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010; 115(16):3224-30. PMC: 2858487. DOI: 10.1182/blood-2009-11-251595. View

Pulsipher M, Young N, Tolar J, Risitano A, Deeg H, Anderlini P . Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials.... Biol Blood Marrow Transplant. 2010; 17(3):291-9. PMC: 3053041. DOI: 10.1016/j.bbmt.2010.10.028. View

Symons H, Fuchs E . Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant. 2008; 42(6):365-77. PMC: 2699592. DOI: 10.1038/bmt.2008.215. View

Viollier R, Socie G, Tichelli A, Bacigalupo A, Korthof E, Marsh J . Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant. 2007; 41(1):45-50. DOI: 10.1038/sj.bmt.1705894. View

Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin J . Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant. 2012; 19(4):552-61. DOI: 10.1016/j.bbmt.2012.12.005. View

10.

Gluckman E, Auerbach A, Horowitz M, Sobocinski K, Ash R, BORTIN M . Bone marrow transplantation for Fanconi anemia. Blood. 1995; 86(7):2856-62. View

11.

Liu H, Sun Z, Geng L, Wang X, Ding K, Tang B . Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival. Bone Marrow Transplant. 2012; 47(9):1186-90. DOI: 10.1038/bmt.2011.251. View

12.

Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H . Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia. Blood. 2011; 118(11):3186-90. DOI: 10.1182/blood-2011-04-349316. View

13.

Symons H, Leffell M, Rossiter N, Zahurak M, Jones R, Fuchs E . Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2009; 16(4):533-42. PMC: 2848533. DOI: 10.1016/j.bbmt.2009.11.022. View

14.

Thakar M, Bonfim C, Sandmaier B, ODonnell P, Ribeiro L, Gooley T . Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia. Pediatr Hematol Oncol. 2012; 29(6):568-78. PMC: 3622043. DOI: 10.3109/08880018.2012.708708. View

15.

Gaziev J, Marziali M, Isgro A, Sodani P, Paciaroni K, Gallucci C . Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. Blood. 2013; 122(15):2751-6. DOI: 10.1182/blood-2013-07-513473. View

16.

Switzer G, Bruce J, Myaskovsky L, DiMartini A, Shellmer D, Confer D . Race and ethnicity in decisions about unrelated hematopoietic stem cell donation. Blood. 2012; 121(8):1469-76. PMC: 3578960. DOI: 10.1182/blood-2012-06-437343. View

17.

Storb R, Thomas E, Buckner C, Clift R, Johnson F, Fefer A . Allogeneic marrow grafting for treatment of aplastic anemia. Blood. 1974; 43(2):157-80. View

18.

Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J . Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000; 37(1):69-80. DOI: 10.1016/s0037-1963(00)90031-3. View

19.

Andreani M, Manna M, Lucarelli G, Tonucci P, Agostinelli F, Ripalti M . Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood. 1996; 87(8):3494-9. View

20.

Eapen M, Le Rademacher J, Antin J, Champlin R, Carreras J, Fay J . Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011; 118(9):2618-21. PMC: 3167362. DOI: 10.1182/blood-2011-05-354001. View